SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues.

[1]  A. Rosenwald,et al.  The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial , 2020, International journal of cancer.

[2]  E. Giné,et al.  Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes. , 2020, Blood.

[3]  A. Schuh,et al.  SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP , 2020, Cell reports.

[4]  D. Rossi,et al.  KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study , 2019, Haematologica.

[5]  L. Kaderali,et al.  Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML , 2019, Nature Communications.

[6]  Andrzej K. Oleś,et al.  Supplementary figures and tables , 2017 .

[7]  R. Siebert,et al.  SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia , 2018, Blood Cancer Journal.

[8]  Allyson E. Koyen,et al.  SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. , 2017, Cell reports.

[9]  L. Kaderali,et al.  SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia , 2016, Nature Medicine.

[10]  W. Klapper,et al.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.

[11]  S. Malek,et al.  A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.

[12]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[13]  F. Lasitschka,et al.  SAMHD1's protein expression profile in humans , 2015, Journal of leukocyte biology.

[14]  D. Bentley,et al.  SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. , 2014, Blood.

[15]  Jonathan C. Fuller,et al.  Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response , 2009, Nature Genetics.